Clinical Trials Insight: 700026815

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2011

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danoprevir (Primary)
Indications Hepatitis C
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors InterMune

01 Oct 2008 Status changed from active, no longer recruiting to completed.
24 Sep 2008 Results from this study will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Oct. 31 - Nov. 4, in San Francisco, California.
29 May 2008 It is expected that results from all dose cohorts will be submitted for possible presentation at this years Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) held in Oct-Nov, reported in an InterMune media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com